Loading company
Cogent Biosciences, Inc.
COGT · Nasdaq · ·
Next earnings: November 6, 2026
$31.66-0.6%Sep 29 close
- 1M
- -8.7%
- 6M
- -10.5%
- 1Y
- +120.5%
- 5Y
- +262.2%
COGT · Nasdaq · ·
Next earnings: November 6, 2026
$31.66-0.6%Sep 29 close
Cogent Biosciences, Inc. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2020, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2020 | 3 months toDec 31, 2019 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $15.3M | -100.00% |
| Profit | -$96.4M | -$73.5M | -31.11% |
| Profit per share | -$0.52 | -$0.53 | +1.89% |
| Free Cash Flow | -$77.6M | -$54.7M | -42.01% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The first half of 2026 has been marked by transformative milestones toward our vision of creating best-in-class therapies for patients fighting rare, mutationally driven diseases as we submitted three New Drug Applications following positive results from each of the bezuclastinib pivotal trials,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Cogent Biosciences, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Cogent Biosciences, Inc. has no earnings call transcript available.